<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Exocrine pancreatic insufficiency</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Exocrine pancreatic insufficiency</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Exocrine pancreatic insufficiency</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tyler Stevens, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Darwin L Conwell, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas G Adler, MD, FACG, AGAF, FASGE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Exocrine pancreatic insufficiency is an under recognized complication of pancreatic disease [<a href="#rid1">1-3</a>]. While patients with advanced exocrine pancreatic insufficiency usually present with abdominal pain and steatorrhea, those with less severe insufficiency may only have mild symptoms. This topic will review the etiology, clinical manifestations, diagnosis, and management of exocrine pancreatic insufficiency. An overview of nutrient absorption, malabsorption, and the evaluation and management of exocrine pancreatic insufficiency in cystic fibrosis are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption"</a> and  <a class="medical medical_review" href="/d/html/4781.html" rel="external">"Overview of nutrient absorption and etiopathogenesis of malabsorption"</a> and  <a class="medical medical_review" href="/d/html/4782.html" rel="external">"Overview of the treatment of malabsorption in adults"</a> and  <a class="medical medical_review" href="/d/html/5885.html" rel="external">"Cystic fibrosis: Assessment and management of pancreatic insufficiency"</a> and  <a class="medical medical_review" href="/d/html/5858.html" rel="external">"Cystic fibrosis: Overview of gastrointestinal disease"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">NORMAL PANCREATIC PHYSIOLOGY</span><span class="headingEndMark"> — </span>The pancreas secretes approximately 1.5 liters of enzyme-rich fluid every day for the digestion of fats, starch, and protein. Normal pancreatic juice is clear, colorless, isotonic, and alkaline. The composition of pancreatic juice differs in basal and stimulated phases. In the fasting state, pancreatic fluid is protein-rich and has a bicarbonate concentration of 80 mEq/L. Stimulation of the pancreas after a meal increases the flow of water and the bicarbonate concentration of pancreatic juice. A large volume of alkaline, enzyme-rich fluid enters the duodenum to neutralize gastric chyme for optimal digestion.</p><p>Pancreatic secretion is controlled by hormonal and neuronal mechanisms. The principal regulatory hormones are <a class="drug drug_general" data-topicid="10259" href="/d/drug information/10259.html" rel="external">secretin</a> and cholecystokinin (CCK). Both are tightly regulated by negative feedback mechanisms. Secretin is released from the duodenal mucosa in response to the presence of acid in the duodenum  (<a class="graphic graphic_figure graphicRef53090" href="/d/graphic/53090.html" rel="external">figure 1</a>). Secretin primarily stimulates the release of bicarbonate and water from the interlobular duct cells and causes a gradual rise in the flow of pancreatic fluid through the ducts and a typical pattern of electrolyte secretion  (<a class="graphic graphic_figure graphicRef82081" href="/d/graphic/82081.html" rel="external">figure 2</a>). As bicarbonate concentration rises to a peak concentration of 120 mEq/L, chloride concentration decreases reciprocally to maintain isotonicity. CCK is released from gut endocrine cells in response to the entry of fat and protein into the proximal intestine  (<a class="graphic graphic_figure graphicRef66575" href="/d/graphic/66575.html" rel="external">figure 3</a>). CCK acts directly and through vagal afferents to stimulate pancreatic acinar cells to release digestive proenzymes. (See  <a class="medical medical_review" href="/d/html/4781.html" rel="external">"Overview of nutrient absorption and etiopathogenesis of malabsorption", section on 'Fat'</a> and  <a class="medical medical_review" href="/d/html/2558.html" rel="external">"Physiology of cholecystokinin"</a> and  <a class="medical medical_review" href="/d/html/2560.html" rel="external">"Secretin"</a>.)</p><p class="headingAnchor" id="H2482574495"><span class="h1">ETIOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>Several conditions are associated with exocrine pancreatic insufficiency [<a href="#rid4">4</a>]. </p><p class="headingAnchor" id="H1109701276"><span class="h2">Chronic pancreatitis</span><span class="headingEndMark"> — </span>Chronic pancreatitis is the most common cause of exocrine pancreatic insufficiency in adults. Progressive inflammatory changes in the pancreas in chronic pancreatitis results in permanent structural damage, which can lead to impairment in exocrine function. (See  <a class="medical medical_review" href="/d/html/5646.html" rel="external">"Etiology and pathogenesis of chronic pancreatitis in adults", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H2001538310"><span class="h2">Cystic fibrosis</span><span class="headingEndMark"> — </span>Cystic fibrosis is caused by mutations in the gene that encodes the cystic fibrosis transmembrane conductance regulator protein. This protein regulates the transport of chloride and water across endothelial cell membranes in the lungs and exocrine glands. Approximately 80 percent of patients with cystic fibrosis also develop progressive pancreatic damage due to the blockage of ductules resulting from inspissated pancreatic secretion. (See  <a class="medical medical_review" href="/d/html/6367.html" rel="external">"Cystic fibrosis: Clinical manifestations and diagnosis", section on 'Pancreatic disease'</a>.) </p><p class="headingAnchor" id="H2612386921"><span class="h2">Pancreatic resection</span><span class="headingEndMark"> — </span>Total or a partial resection of the pancreas may result in varying degrees of exocrine pancreatic insufficiency due to reduction of glandular tissue or postoperative pancreatic duct occlusion. Extensive denervation following lymph node dissection can result in postcibal asynchrony and decreased pancreatic stimulation. (See  <a class="medical medical_review" href="/d/html/4775.html" rel="external">"Chronic complications of the short bowel syndrome in adults"</a>.)</p><p class="headingAnchor" id="H172155748"><span class="h2">Pancreatic duct obstruction</span><span class="headingEndMark"> — </span>Atrophy of the pancreas secondary to pancreatic/ampullary tumor-induced pancreatic duct obstruction and fibrosis can lead to exocrine pancreatic insufficiency [<a href="#rid5">5,6</a>]. </p><p class="headingAnchor" id="H2887820419"><span class="h2">Shwachman-Diamond syndrome</span><span class="headingEndMark"> — </span>Shwachman-Diamond syndrome is an autosomal recessive syndrome that generally presents in infancy with bone marrow failure, particularly neutropenia, and exocrine pancreatic dysfunction. (See  <a class="medical medical_review" href="/d/html/5914.html" rel="external">"Shwachman-Diamond syndrome"</a>.)</p><p class="headingAnchor" id="H1711766750"><span class="h2">Other</span><span class="headingEndMark"> — </span>Patients with gastrinoma (Zollinger-Ellison syndrome) may develop exocrine pancreatic insufficiency due to inactivation of pancreatic enzymes by gastric acid. Small bowel mucosal disease (eg, celiac disease, Crohn disease) can result in decreased cholecystokinin release, which in turn can result in reduced pancreatic secretion. Patients with a history of complex foregut surgery (Roux-en-Y gastric bypass, pancreaticoduodenectomy, duodenal switch, etc) are also at moderate risk for exocrine pancreatic insufficiency. Loss of the pylorus, dumping syndrome, and motility disorders following surgery may result in asynchrony as delivery of pancreatic enzymes may not match the delivery of the meal in the upper intestine. Other rare causes of exocrine pancreatic insufficiency include hereditary hemochromatosis, which results in progressive iron deposition in the pancreas. (See  <a class="medical medical_review" href="/d/html/7167.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemochromatosis"</a> and  <a class="medical medical_review" href="/d/html/1464.html" rel="external">"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency"</a> and  <a class="medical medical_review" href="/d/html/2558.html" rel="external">"Physiology of cholecystokinin"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H1651015612"><span class="h2">Asymptomatic/mild symptoms</span><span class="headingEndMark"> — </span>Patients with mild exocrine pancreatic insufficiency may be asymptomatic or have mild abdominal discomfort and bloating with normal-appearing bowel movements.</p><p class="headingAnchor" id="H2665891831"><span class="h2">Moderate to severe symptoms</span><span class="headingEndMark"> — </span>Advanced exocrine pancreatic insufficiency results in maldigestion of fat and protein and weight loss. Overt steatorrhea does not occur until approximately 90 percent of glandular function has been lost [<a href="#rid7">7</a>]. Patients with steatorrhea report loose, greasy, foul-smelling stools that are difficult to flush. Other symptoms include bloating, cramping, and increased flatulence. Although clinically symptomatic vitamin deficiency is rare, metabolic bone disease and impaired night vision have been observed in patients with chronic pancreatitis [<a href="#rid8">8,9</a>]. (See  <a class="medical medical_review" href="/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption"</a>.)</p><p class="headingAnchor" id="H1648244338"><span class="h1">LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>Patients with severe exocrine pancreatic insufficiency have elevated levels of fecal fat. Fat malabsorption predisposes patients to deficiencies of the fat soluble vitamins A, D, E, and K [<a href="#rid10">10,11</a>]. Rarely, patients may also have vitamin B12 deficiency because a reduction in intestinal pH adversely affects the transfer of vitamin B12 from R protein to intrinsic factor [<a href="#rid12">12,13</a>]. (See  <a class="medical medical_review" href="/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption"</a> and  <a class="medical medical_review" href="/d/html/5649.html" rel="external">"Chronic pancreatitis: Clinical manifestations and diagnosis in adults"</a> and  <a class="medical medical_review" href="/d/html/7153.html" rel="external">"Causes and pathophysiology of vitamin B12 and folate deficiencies", section on 'Pancreatic insufficiency'</a>.)</p><p class="headingAnchor" id="H3367394501"><span class="h1">IMAGING FINDINGS</span><span class="headingEndMark"> — </span>Cross-sectional imaging (computed tomography scan, magnetic resonance imaging, and endoscopic ultrasound) cannot identify exocrine pancreatic insufficiency but can identify underlying pancreatic diseases. In patients with chronic pancreatitis, abdominal imaging may demonstrate calcifications, ductal dilatation, enlargement of the pancreas, and peripancreatic fluid collections. Patients with advanced chronic pancreatitis, cystic fibrosis, Shwachman-Diamond syndrome, and advanced hemochromatosis may have evidence of pancreatic atrophy. </p><p class="headingAnchor" id="H1172680175"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of exocrine pancreatic insufficiency includes other causes of chronic diarrhea and steatorrhea. These include small intestinal bacterial overgrowth, celiac disease, and giardiasis. Exocrine pancreatic insufficiency can be distinguished from these causes based on history and laboratory studies. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small intestinal bacterial overgrowth</strong> – Patients with small intestinal bacterial overgrowth (SIBO) present with nonspecific symptoms of bloating, flatulence, abdominal discomfort, or steatorrhea. The diagnosis of SIBO is established by a carbohydrate breath test (eg, glucose or <a class="drug drug_general" data-topicid="9543" href="/d/drug information/9543.html" rel="external">lactulose</a> breath test) or jejunal aspirate culture. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Celiac disease</strong> – Patients with celiac disease can present with chronic diarrhea or steatorrhea but have elevated celiac serologies (IgA anti-tissue transglutaminase antibody). Some patients with celiac disease may have secondary exocrine pancreatic insufficiency that resolves with mucosal inflammation on a gluten-free diet. (See  <a class="medical medical_review" href="/d/html/4771.html" rel="external">"Diagnosis of celiac disease in adults", section on 'Diagnostic approach'</a> and  <a class="medical medical_review" href="/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults", section on 'Gastrointestinal manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Giardiasis</strong> – <em>Giardia duodenalis</em> is a protozoan parasite capable of causing epidemic or sporadic diarrheal illness. Acute and chronic giardiasis can cause diarrhea, malaise, abdominal cramps, and weight loss. The diagnosis of giardiasis can be established with antigen detection assays, nucleic acid detection assays, or stool examination. (See  <a class="medical medical_review" href="/d/html/5723.html" rel="external">"Giardiasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p>The differential diagnosis for other causes of chronic diarrhea is broad and is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2591.html" rel="external">"Approach to the adult with chronic diarrhea in resource-abundant settings"</a>.)</p><p class="headingAnchor" id="H3089255908"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3886432725"><span class="h2">Diagnostic approach</span><span class="headingEndMark"> — </span>The diagnosis of exocrine pancreatic insufficiency should be suspected in patients with chronic diarrhea/steatorrhea and chronic abdominal pain. Exocrine pancreatic insufficiency should also be suspected in patients with milder symptoms of bloating with overt morphological abnormalities on pancreatic imaging that are suggestive of chronic pancreatitis (eg, calcifications and/or main pancreatic duct dilation). </p><p>In patients with well-established chronic pancreatitis or underlying pancreatic disease, a clinical diagnosis can be made based on the patient's symptoms. However, if the diagnosis is unclear or in those without well-established pancreatic disease, we begin with an indirect test of pancreas function (fecal elastase-1) to establish the diagnosis of exocrine pancreatic insufficiency. Response to a therapeutic trial of pancreatic enzymes should not be relied upon to diagnose exocrine pancreatic insufficiency in patients with nonspecific symptoms as the response may be due to placebo effect and result in delays in diagnosis [<a href="#rid4">4</a>]. </p><p class="headingAnchor" id="H3062825654"><span class="h2">Indirect pancreatic function tests</span><span class="headingEndMark"> — </span>Indirect tests measure the consequence of exocrine insufficiency (maldigestion). Indirect tests are simpler, easier to perform, and less expensive as compared with direct pancreas function tests. Their main role is in diagnosis of advanced exocrine pancreatic insufficiency. They are much less sensitive as compared with direct tests for diagnosis of earlier stages of exocrine pancreatic insufficiency. Other disadvantages include false positive results with non-pancreatic gastrointestinal diseases and the need for stool collection.</p><p class="headingAnchor" id="H3647374121"><span class="h3">Fecal elastase-1</span><span class="headingEndMark"> — </span>Fecal elastase is the most sensitive and specific indirect test of pancreatic function, and the most widely available and commonly performed pancreatic function test in clinical practice. Fecal elastase-1 is an enzymatic product of pancreatic secretion that remains relatively stable during transport through the gastrointestinal tract. There is a direct correlation in pancreatic elastase-1 concentrations in pancreatic fluid and stool [<a href="#rid14">14,15</a>]. Fecal elastase-1 must be performed on a semi-solid or solid stool specimen. Watery diarrhea may dilute the fecal specimen and produce false-positive results. This limitation can be ameliorated by lyophilizing (concentrating) the stool sample [<a href="#rid16">16</a>]. </p><p>Fecal elastase-1 &lt;200 mcg/g is considered abnormal. Levels &lt;100 mg/g of stool are more consistent with EPI, while levels of 100 to 200 mg/g of stool are indeterminate for exocrine pancreatic insufficiency. The sensitivity of fecal elastase-1 for mild, moderate, and severe exocrine pancreatic insufficiency in patients with chronic pancreatitis are 63, 100, and 100 percent, respectively. Fecal elastase has a specificity of 93 percent in patients with exocrine pancreatic insufficiency [<a href="#rid14">14,17-19</a>]. Exogenous pancreatic enzyme replacement therapy does not alter fecal elastase test results.</p><p class="headingAnchor" id="H3071150010"><span class="h3">Other</span><span class="headingEndMark"> — </span>Other tests are not routinely used to measure pancreatic function.</p><p class="headingAnchor" id="H1778825493"><span class="h4">Fecal chymotrypsin</span><span class="headingEndMark"> — </span>Fecal chymotrypsin is also an enzymatic product of pancreatic secretion that can be used to detect pancreatic insufficiency. However, chymotrypsin has a lower sensitivity and specificity for exocrine pancreatic insufficiency as compared with fecal elastase-1 [<a href="#rid20">20</a>]. The sensitivity of fecal chymotrypsin for mild to moderate and advanced pancreatic insufficiency is 49 and 85 percent, respectively [<a href="#rid21">21</a>]. Chymotrypsin is variably affected during intestinal transport and may be diluted in the presence of concomitant diarrhea. Since chymotrypsin is present in commercially available enzymes, patients must stop exogenous enzymes for two days prior to testing. </p><p class="headingAnchor" id="H56757005"><span class="h4">Serum trypsinogen</span><span class="headingEndMark"> — </span>Serum trypsinogen is an inexpensive and widely available test that reflects pancreatic acinar cell mass [<a href="#rid22">22,23</a>]. Serum trypsinogen has a high sensitivity for advanced exocrine pancreatic insufficiency when trypsinogen levels are less than 20 ng/mL [<a href="#rid24">24</a>]. However, the test has low sensitivity for diagnosing less severe exocrine pancreatic insufficiency when trypsinogen levels are between 20 and 29 ng/mL. In addition, serum trypsinogen is not specific for exocrine pancreatic insufficiency and levels rise with acute pancreatitis and abdominal pain of nonpancreatic origin [<a href="#rid22">22,23</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Direct pancreatic function tests</span><span class="headingEndMark"> — </span>Direct pancreatic function tests are the most sensitive diagnostic tests for exocrine pancreatic insufficiency [<a href="#rid25">25</a>]. They involve stimulation of the pancreas through the administration of hormonal secretagogues after which duodenal fluid is collected and analyzed to directly quantify pancreatic secretory content (ie, enzymes and bicarbonate). Limitations include the lack of standardization of testing protocol and normal ranges, limited availability of expertise needed to perform the test, and poor patient tolerance [<a href="#rid20">20,26</a>]. Cholecystokinin (CCK) and <a class="drug drug_general" data-topicid="10259" href="/d/drug information/10259.html" rel="external">secretin</a> have both been used to stimulate pancreatic secretion [<a href="#rid27">27-29</a>]. However, it is unclear which secretagogue offers the best sensitivity for early pancreatic insufficiency. Studies evaluating the performance of direct pancreas function tests in patients with established chronic pancreatitis on imaging have demonstrated a sensitivity of 72 to 94 percent [<a href="#rid25">25,30-39</a>]. </p><p class="headingAnchor" id="H2397234131"><span class="h3">Secretin test</span><span class="headingEndMark"> — </span>Direct pancreas function testing using <a class="drug drug_general" data-topicid="10259" href="/d/drug information/10259.html" rel="external">secretin</a> stimulation measures the ability of ductal cells to produce bicarbonate. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Traditional test</strong> – The traditional direct pancreas function test requires fluoroscopic placement of an oroduodenal collection tube (eg, Dreiling tube) with gastric and duodenal ports  (<a class="graphic graphic_diagnosticimage graphicRef72009" href="/d/graphic/72009.html" rel="external">image 1</a>). After a test dose (0.2 mcg) of synthetic <a class="drug drug_general" data-topicid="10259" href="/d/drug information/10259.html" rel="external">secretin</a>, a full dose (0.2 mcg/kg) is administered as an intravenous bolus. Duodenal fluid is continuously collected in 15-minute aliquots for one hour. Fluid is analyzed for bicarbonate concentration, volume, and total bicarbonate output. A bicarbonate concentration less than 80 mEq/L in all of the four aliquots is diagnostic of exocrine pancreatic insufficiency [<a href="#rid40">40</a>]. Severe exocrine pancreatic insufficiency is characterized by a peak bicarbonate concentration less than 50 mEq/L. Total volume and bicarbonate output have been used as secondary diagnostic parameters when bicarbonate concentration is equivocal. However, bicarbonate output and fluid volume are notoriously inaccurate measures because of the incomplete recovery of duodenal fluid. A shortened collection period has also been evaluated but has significantly lower accuracy in diagnosing pancreatic insufficiency as compared with the standard one-hour collection [<a href="#rid41">41,42</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endoscopic test</strong> – Endoscopically-assisted and purely endoscopic pancreatic function test are performed under sedation and are better tolerated as compared with tradition direct pancreas function test [<a href="#rid43">43</a>]. In endoscopically-assisted pancreas function tests, an endoscopically placed Dreiling or Liguory tube is used for duodenal fluid collection. In contrast, in purely endoscopic pancreas function testing, duodenal fluid is collected through the endoscope into a specimen trap.</p><p></p><p class="bulletIndent1">The protocol for the <a class="drug drug_general" data-topicid="10259" href="/d/drug information/10259.html" rel="external">secretin</a> endoscopic pancreatic function test is similar to the traditional secretin test protocol. Duodenal aspirates are obtained 0, 15, 30, 45, and 60 minutes after administration of secretin; however, aspiration at 30 to 45 minutes can simplify the test and appears to be sufficient for screening [<a href="#rid44">44</a>]. A peak bicarbonate concentration &lt;80 mEq/L is considered abnormal for the one-hour method. A cutoff of 75 mEq/L is used for the shortened test. The secretin endoscopic pancreatic function test method replicates the well-known pancreatic secretory patterns observed with collection tubes  (<a class="graphic graphic_figure graphicRef66606" href="/d/graphic/66606.html" rel="external">figure 4</a>) and is comparable in accuracy to the traditional secretin test [<a href="#rid45">45-47</a>]. In one retrospective study that included 25 patients with chronic pancreatitis, the sensitivity and specificity of endoscopic secretin pancreas function testing for chronic pancreatitis was 86 and 67 percent, respectively [<a href="#rid48">48</a>]. Standard doses of sedation do not appear to decrease pancreas secretion, but caution in interpretation of abnormal results is needed when large amounts of analgesia are needed for endoscopy [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent1">Intraductal collection of secretin-stimulated pure pancreatic juice at the time of endoscopic retrograde cholangiopancreatography has also been evaluated as an alternative to standard <a class="drug drug_general" data-topicid="10259" href="/d/drug information/10259.html" rel="external">secretin</a> testing because it permits simultaneous evaluation of pancreatic structure and function. However, studies of intraductal secretin tests have yielded mixed results and the procedure carries the risk of acute pancreatitis [<a href="#rid50">50-53</a>]. </p><p></p><p class="headingAnchor" id="H8"><span class="h3">CCK test</span><span class="headingEndMark"> — </span>Use of CCK receptor agonist (eg, cerulein) as a hormonal stimulant provides information on the enzyme secretory capacity of the pancreas. However, thresholds for lipase concentrations have not been well established and results from studies have been conflicting [<a href="#rid54">54-56</a>]. Traditionally, this test requires the placement of two tubes: a double-lumen duodenal tube and a single-lumen gastric tube [<a href="#rid29">29</a>]. The gastric tube continuously collects and discards gastric fluid to prevent acidification of the duodenum. One duodenal lumen continuously collects duodenal drainage fluid. The other lumen perfuses a mannitol-saline solution with a non-absorbable marker (polyethylene glycol [PEG]). An accurate determination is made of enzyme concentration, enzyme output, and fluid volume based upon recovery of the PEG marker. CCK pancreas function test has also been performed endoscopically [<a href="#rid55">55</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breath</strong> <strong>tests</strong> – Breath tests for exocrine pancreatic insufficiency involve the oral administration of 13C-marked substrates with a test meal [<a href="#rid57">57,58</a>]. These substrates are hydrolyzed within the intestinal lumen in proportion to the amount of pancreatic lipase activity. The hydrolyzed products are absorbed and metabolized, and eventually released across the pulmonary endothelium as 13CO2. Mass spectrometry or infrared analysis is used to quantify 13CO2. Like other indirect tests, breath tests quantify fat malabsorption and are therefore nonspecific and inaccurate for the diagnosis of mild exocrine pancreatic insufficiency. In the United States, breath tests have not been approved for diagnosis of exocrine insufficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10259" href="/d/drug information/10259.html" rel="external">Secretin</a>-<strong>enhanced</strong> <strong>diffusion weighted</strong> <strong>magnetic resonance imaging </strong>– Secretin-enhanced magnetic resonance cholangiopancreatography also allows timed assessments of duodenal filling, which provides an estimation of pancreatic exocrine function. Secretin stimulates both pancreatic ductal secretion of water and pancreatic blood flow. Diffusion weight magnetic resonance imaging (MRI) permits detection of the mobility of water molecules and increased capillary blood flow in pancreatic parenchyma. The apparent diffusion coefficient is a calculated measure that integrates both diffusion and perfusion. Studies are needed to compare diffusion weighted MRI with direct pancreatic function tests [<a href="#rid59">59,60</a>].</p><p></p><p class="headingAnchor" id="H2662807133"><span class="h1">ESTABLISHING THE ETIOLOGY</span><span class="headingEndMark"> — </span>Once functional tests have established the diagnosis of exocrine pancreatic insufficiency, it is necessary to determine the underlying etiology  (<a class="graphic graphic_table graphicRef63433" href="/d/graphic/63433.html" rel="external">table 1</a>). In patients in whom the history can often clearly point to the underlying etiology, we do not perform additional evaluation in the absence of worrisome clinical features (eg, new onset of steatorrhea with weight loss). Historical clues that may be indicative of a specific etiology include a history of cystic fibrosis, chronic pancreatitis, and gastric/small bowel/pancreatic resection. In patients with new onset steatorrhea and weight loss, we perform an abdominal computerized tomography scan or endoscopic ultrasound to rule out pancreatic ductal adenocarcinoma. (See <a class="local">'Etiology and pathogenesis'</a> above.)</p><p>Exocrine pancreatic insufficiency may also be associated with celiac disease, gastrinoma, and liver disease. Additional testing for these conditions should be performed in patients with a history or physical examination findings suggestive of these disorders. (See  <a class="medical medical_review" href="/d/html/4771.html" rel="external">"Diagnosis of celiac disease in adults", section on 'Diagnostic approach'</a> and  <a class="medical medical_review" href="/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H649708664"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The mainstay of management in patients with symptoms of maldigestion and steatorrhea due to exocrine pancreatic insufficiency is administration of exogenous pancreatic enzymes. Patients with exocrine pancreatic insufficiency are also at risk for deficiencies of fat-soluble vitamins and other micronutrients, and bone disease. Prevention and monitoring for these complications are discussed separately. (See  <a class="medical medical_review" href="/d/html/5885.html" rel="external">"Cystic fibrosis: Assessment and management of pancreatic insufficiency", section on 'Management'</a> and  <a class="medical medical_review" href="/d/html/4782.html" rel="external">"Overview of the treatment of malabsorption in adults"</a> and  <a class="medical medical_review" href="/d/html/5647.html" rel="external">"Chronic pancreatitis: Management", section on 'Management of pancreatic insufficiency'</a>.)</p><p class="headingAnchor" id="H1452200600"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112065.html" rel="external">"Society guideline links: Chronic pancreatitis and pancreatic exocrine insufficiency"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology and pathogenesis</strong> – Exocrine pancreatic insufficiency results from loss of pancreatic parenchyma (eg, chronic pancreatitis), inadequate pancreatic stimulation (eg, pancreatic surgical resection), pancreatic duct obstruction, or pancreatic enzyme inactivation (eg, gastrinoma)  (<a class="graphic graphic_table graphicRef63433" href="/d/graphic/63433.html" rel="external">table 1</a>). (See <a class="local">'Etiology and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong>  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with mild exocrine pancreatic insufficiency may be asymptomatic or have mild abdominal discomfort and bloating with normal-appearing bowel movements. Overt steatorrhea does not occur until approximately 90 percent of glandular function has been lost. Advanced exocrine pancreatic insufficiency results in maldigestion of fat and protein and weight loss. Patients with steatorrhea report loose, greasy, foul-smelling stools that are difficult to flush. Other symptoms include bloating, cramping, and increased flatulence. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with severe exocrine pancreatic insufficiency have elevated levels of fecal fat. Malabsorption of the fat-soluble vitamins (A, D, E, K) and vitamin B12 may also occur. (See <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging findings</strong> – In patients with chronic pancreatitis, calcifications, ductal dilatation or atrophy of the pancreas may be detected on abdominal imaging. Patients with advanced chronic pancreatitis, cystic fibrosis, Shwachman-Diamond syndrome, and advanced hemochromatosis may have pancreatic atrophy on imaging. (See <a class="local">'Imaging findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of exocrine pancreatic insufficiency should be suspected in patients with underlying conditions associated with exocrine insufficiency, and who have postprandial cramping abdominal pain, bloating, chronic diarrhea, or steatorrhea. Exocrine pancreatic insufficiency should also be suspected in patients with milder symptoms of bloating with morphological abnormalities on pancreatic imaging that are suggestive of chronic pancreatitis (eg, calcifications and/or main pancreatic duct dilation). In patients with well-established chronic pancreatitis or underlying pancreatic disease, a clinical diagnosis can be made based on the patient's symptoms. However if the diagnosis is unclear or in those without well-established pancreatic disease, we begin with an indirect test of pancreas function (fecal elastase-1) to establish the diagnosis of exocrine pancreatic insufficiency. (See <a class="local">'Diagnostic approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determining the underlying etiology</strong> – Once a diagnosis of exocrine pancreatic insufficiency is made, it is necessary to determine the underlying etiology  (<a class="graphic graphic_table graphicRef63433" href="/d/graphic/63433.html" rel="external">table 1</a>). In patients in whom the history can clearly point to the underlying etiology, we do not perform additional evaluation in the absence of worrisome clinical features (eg, new onset of steatorrhea with weight loss). In patients with new onset steatorrhea and weight loss, we perform an abdominal CT scan or endoscopic ultrasound to rule out pancreatic ductal adenocarcinoma. (See <a class="local">'Establishing the etiology'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lagerlof HO. Pancreatic function and pancreatic disease: studied by means of secretin. Acta Med Scand 1942; 128:1.</a></li><li><a class="nounderline abstract_t">Chiray M, Jeandel A, Salmon A. L'exploration clinique du pancreas et l'injection intraveneuse de secretine purifiee. Presse Med 1930; 38:977.</a></li><li><a class="nounderline abstract_t">DREILING DA, HOLLANDER F. Studies in pancreatic function; preliminary series of clinical studies with the secretin test. Gastroenterology 1948; 11:714.</a></li><li><a class="nounderline abstract_t">Whitcomb DC, Buchner AM, Forsmark CE. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review. Gastroenterology 2023; 165:1292.</a></li><li><a class="nounderline abstract_t">Perez MM, Newcomer AD, Moertel CG, et al. Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer. Cancer 1983; 52:346.</a></li><li><a class="nounderline abstract_t">Bartel MJ, Asbun H, Stauffer J, Raimondo M. Pancreatic exocrine insufficiency in pancreatic cancer: A review of the literature. Dig Liver Dis 2015; 47:1013.</a></li><li><a class="nounderline abstract_t">DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. N Engl J Med 1973; 288:813.</a></li><li><a class="nounderline abstract_t">Toskes PP, Dawson W, Curington C, et al. Non-diabetic retinal abnormalities in chronic pancreatitis. N Engl J Med 1979; 300:942.</a></li><li><a class="nounderline abstract_t">Morán CE, Sosa EG, Martinez SM, et al. Bone mineral density in patients with pancreatic insufficiency and steatorrhea. Am J Gastroenterol 1997; 92:867.</a></li><li><a class="nounderline abstract_t">Dutta SK, Bustin MP, Russell RM, Costa BS. Deficiency of fat-soluble vitamins in treated patients with pancreatic insufficiency. Ann Intern Med 1982; 97:549.</a></li><li><a class="nounderline abstract_t">Nakamura T, Takebe K, Imamura K, et al. Fat-soluble vitamins in patients with chronic pancreatitis (pancreatic insufficiency). Acta Gastroenterol Belg 1996; 59:10.</a></li><li><a class="nounderline abstract_t">Chen WL, Morishita R, Eguchi T, et al. Clinical usefulness of dual-label Schilling test for pancreatic exocrine function. Gastroenterology 1989; 96:1337.</a></li><li><a class="nounderline abstract_t">Glasbrenner B, Malfertheiner P, Büchler M, et al. Vitamin B12 and folic acid deficiency in chronic pancreatitis: a relevant disorder? Klin Wochenschr 1991; 69:168.</a></li><li><a class="nounderline abstract_t">Löser C, Möllgaard A, Fölsch UR. Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut 1996; 39:580.</a></li><li><a class="nounderline abstract_t">Stein J, Jung M, Sziegoleit A, et al. Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. Clin Chem 1996; 42:222.</a></li><li><a class="nounderline abstract_t">Fischer B, Hoh S, Wehler M, et al. Faecal elastase-1: lyophilization of stool samples prevents false low results in diarrhoea. Scand J Gastroenterol 2001; 36:771.</a></li><li><a class="nounderline abstract_t">Domínguez-Muñoz JE, Hieronymus C, Sauerbruch T, Malfertheiner P. Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Am J Gastroenterol 1995; 90:1834.</a></li><li><a class="nounderline abstract_t">Gullo L, Ventrucci M, Tomassetti P, et al. Fecal elastase 1 determination in chronic pancreatitis. Dig Dis Sci 1999; 44:210.</a></li><li><a class="nounderline abstract_t">Beharry S, Ellis L, Corey M, et al. How useful is fecal pancreatic elastase 1 as a marker of exocrine pancreatic disease? J Pediatr 2002; 141:84.</a></li><li><a class="nounderline abstract_t">Lankisch PG, Schreiber A, Otto J. Pancreolauryl test. Evaluation of a tubeless pancreatic function test in comparison with other indirect and direct tests for exocrine pancreatic function. Dig Dis Sci 1983; 28:490.</a></li><li><a class="nounderline abstract_t">Niederau C, Grendell JH. Diagnosis of chronic pancreatitis. Gastroenterology 1985; 88:1973.</a></li><li><a class="nounderline abstract_t">Couper RT, Corey M, Durie PR, et al. Longitudinal evaluation of serum trypsinogen measurement in pancreatic-insufficient and pancreatic-sufficient patients with cystic fibrosis. J Pediatr 1995; 127:408.</a></li><li><a class="nounderline abstract_t">Ventrucci M, Pezzilli R, Gullo L, et al. Role of serum pancreatic enzyme assays in diagnosis of pancreatic disease. Dig Dis Sci 1989; 34:39.</a></li><li><a class="nounderline abstract_t">Jacobson DG, Curington C, Connery K, Toskes PP. Trypsin-like immunoreactivity as a test for pancreatic insufficiency. N Engl J Med 1984; 310:1307.</a></li><li><a class="nounderline abstract_t">Lambiase L, Forsmark CE, Toskes PP. Secretin test diagnoses chronic pancreatitis earlier than ERCP (abstract). Gastroenterology 1993; 104:315.</a></li><li><a class="nounderline abstract_t">HANSKY J, TISCORNIA OM, DREILING DA, JANOWITZ HD. RELATIONSHIP BETWEEN MAXIMAL SECRETORY OUTPUT AND WEIGHT OF THE PANCREAS IN THE DOG. Proc Soc Exp Biol Med 1963; 114:654.</a></li><li><a class="nounderline abstract_t">Banwell JG, Northam BE, Cooke WT. Secretory response of the human pancreas to continuous intravenous infusion of pancreozymin-cholecystokinin (Cecekin). Gut 1967; 8:380.</a></li><li><a class="nounderline abstract_t">Ribet A, Tournut R, Duffaut M, Vaysse N. Use of caerulein with submaximal doses of secretin as a test of pancreatic function in man. Gut 1976; 17:431.</a></li><li><a class="nounderline abstract_t">Go VL, Hofmann AF, Summerskill WH. Simultaneous measurements of total pancreatic, biliary, and gastric outputs in man using a perfusion technique. Gastroenterology 1970; 58:321.</a></li><li><a class="nounderline abstract_t">Valentini M, Cavallini G, Vantini I, et al. A comparative evaluation of endoscopic retrograde cholangiopancreatography and the secretin-cholecystokinin test in the diagnosis of chronic pancreatitis: a multicentre study in 124 patients. Endoscopy 1981; 13:64.</a></li><li><a class="nounderline abstract_t">Dobrilla G, Fratton A, Valentini M, et al. Endoscopic retrograde pancreatography and secretin-pancreozymin test in diagnosis of chronic pancreatitis: a comparative evaluation. Endoscopy 1976; 9:118.</a></li><li><a class="nounderline abstract_t">Mee AS, Girdwood AH, Walker E, et al. Comparison of the oral (PABA) pancreatic function test, the secretin-pancreozymin test and endoscopic retrograde pancreatography in chronic alcohol induced pancreatitis. Gut 1985; 26:1257.</a></li><li><a class="nounderline abstract_t">Ketwaroo G, Brown A, Young B, et al. Defining the accuracy of secretin pancreatic function testing in patients with suspected early chronic pancreatitis. Am J Gastroenterol 2013; 108:1360.</a></li><li><a class="nounderline abstract_t">Rolny P, Jagenburg R. The secretin-CCK test and a modified Lundh test. A comparative study. Scand J Gastroenterol 1978; 13:927.</a></li><li><a class="nounderline abstract_t">Rolny P, Lukes PJ, Gamklou R, et al. A comparative evaluation of endoscopic retrograde pancreatography and secretin-CCK test in the diagnosis of pancreatic disease. Scand J Gastroenterol 1978; 13:777.</a></li><li><a class="nounderline abstract_t">Malfertheiner P, Büchler M, Stanescu A, Ditschuneit H. Exocrine pancreatic function in correlation to ductal and parenchymal morphology in chronic pancreatitis. Hepatogastroenterology 1986; 33:110.</a></li><li><a class="nounderline abstract_t">Braganza JM, Hunt LP, Warwick F. Relationship between pancreatic exocrine function and ductal morphology in chronic pancreatitis. Gastroenterology 1982; 82:1341.</a></li><li><a class="nounderline abstract_t">Heij HA, Obertop H, Schmitz PI, et al. Evaluation of the secretin-cholecystokinin test for chronic pancreatitis by discriminant analysis. Scand J Gastroenterol 1986; 21:35.</a></li><li><a class="nounderline abstract_t">Bozkurt T, Braun U, Leferink S, et al. Comparison of pancreatic morphology and exocrine functional impairment in patients with chronic pancreatitis. Gut 1994; 35:1132.</a></li><li><a class="nounderline abstract_t">Dreiling DA. Pancreatic secretory testing in 1974. Gut 1975; 16:653.</a></li><li><a class="nounderline abstract_t">Catalano MF, Lahoti S, Geenen JE, Hogan WJ. Prospective evaluation of endoscopic ultrasonography, endoscopic retrograde pancreatography, and secretin test in the diagnosis of chronic pancreatitis. Gastrointest Endosc 1998; 48:11.</a></li><li><a class="nounderline abstract_t">Draganov P, George S, Toskes PP, Forsmark CE. Is a 15-minute collection of duodenal secretions after secretin stimulation sufficient to diagnose chronic pancreatitis? Pancreas 2004; 28:89.</a></li><li><a class="nounderline abstract_t">Moolsintong P, Burton FR. Pancreatic function testing is best determined by the extended endoscopic collection technique. Pancreas 2008; 37:418.</a></li><li><a class="nounderline abstract_t">Stevens T, Conwell DL, Zuccaro G Jr, et al. The efficiency of endoscopic pancreatic function testing is optimized using duodenal aspirates at 30 and 45 minutes after intravenous secretin. Am J Gastroenterol 2007; 102:297.</a></li><li><a class="nounderline abstract_t">Stevens T, Conwell DL, Zuccaro G, et al. Electrolyte composition of endoscopically collected duodenal drainage fluid after synthetic porcine secretin stimulation in healthy subjects. Gastrointest Endosc 2004; 60:351.</a></li><li><a class="nounderline abstract_t">Stevens T, Conwell DL, Zuccaro G Jr, et al. A randomized crossover study of secretin-stimulated endoscopic and dreiling tube pancreatic function test methods in healthy subjects. Am J Gastroenterol 2006; 101:351.</a></li><li><a class="nounderline abstract_t">Stevens T, Conwell DL, Zuccaro G Jr, et al. A prospective crossover study comparing secretin-stimulated endoscopic and Dreiling tube pancreatic function testing in patients evaluated for chronic pancreatitis. Gastrointest Endosc 2008; 67:458.</a></li><li><a class="nounderline abstract_t">Albashir S, Bronner MP, Parsi MA, et al. Endoscopic ultrasound, secretin endoscopic pancreatic function test, and histology: correlation in chronic pancreatitis. Am J Gastroenterol 2010; 105:2498.</a></li><li><a class="nounderline abstract_t">Conwell DL, Zuccaro G, Purich E, et al. The effect of moderate sedation on exocrine pancreas function in normal healthy subjects: a prospective, randomized, cross-over trial using the synthetic porcine secretin stimulated Endoscopic Pancreatic Function Test (ePFT). Am J Gastroenterol 2005; 100:1161.</a></li><li><a class="nounderline abstract_t">Denyer ME, Cotton PB. Pure pancreatic juice studies in normal subjects and patients with chronic pancreatitis. Gut 1979; 20:89.</a></li><li><a class="nounderline abstract_t">Ochi K, Harada H, Mizushima T, et al. Intraductal secretin test is as useful as duodenal secretin test in assessing exocrine pancreatic function. Dig Dis Sci 1997; 42:492.</a></li><li><a class="nounderline abstract_t">Gregg JA, Sharma MM. Endoscopic measurement of pancreatic juice secretory flow rates and pancreatic secretory pressures after secretin administration in human controls and in patients with acute relapsing pancreatitis, chronic pancreatitis, and pancreatic cancer. Am J Surg 1978; 136:569.</a></li><li><a class="nounderline abstract_t">Draganov P, Patel A, Fazel A, et al. Prospective evaluation of the accuracy of the intraductal secretin stimulation test in the diagnosis of chronic pancreatitis. Clin Gastroenterol Hepatol 2005; 3:695.</a></li><li><a class="nounderline abstract_t">Stevens T, Dumot JA, Zuccaro G Jr, et al. Evaluation of duct-cell and acinar-cell function and endosonographic abnormalities in patients with suspected chronic pancreatitis. Clin Gastroenterol Hepatol 2009; 7:114.</a></li><li><a class="nounderline abstract_t">Conwell DL, Zuccaro G Jr, Vargo JJ, et al. An endoscopic pancreatic function test with cholecystokinin-octapeptide for the diagnosis of chronic pancreatitis. Clin Gastroenterol Hepatol 2003; 1:189.</a></li><li><a class="nounderline abstract_t">Stevens T, Parsi MA. Update on endoscopic pancreatic function testing. World J Gastroenterol 2011; 17:3957.</a></li><li><a class="nounderline abstract_t">Sun DY, Jiang YB, Rong L, et al. Clinical application of 13C-Hiolein breath test in assessing pancreatic exocrine insufficiency. Hepatobiliary Pancreat Dis Int 2003; 2:449.</a></li><li><a class="nounderline abstract_t">Ritz MA, Fraser RJ, Di Matteo AC, et al. Evaluation of the 13C-triolein breath test for fat malabsorption in adult patients with cystic fibrosis. J Gastroenterol Hepatol 2004; 19:448.</a></li><li><a class="nounderline abstract_t">Erturk SM, Ichikawa T, Motosugi U, et al. Diffusion-weighted MR imaging in the evaluation of pancreatic exocrine function before and after secretin stimulation. Am J Gastroenterol 2006; 101:133.</a></li><li><a class="nounderline abstract_t">Balci NC, Smith A, Momtahen AJ, et al. MRI and S-MRCP findings in patients with suspected chronic pancreatitis: correlation with endoscopic pancreatic function testing (ePFT). J Magn Reson Imaging 2010; 31:601.</a></li></ol></div><div id="topicVersionRevision">Topic 4779 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pancreatic function and pancreatic disease: studied by means of secretin</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : L'exploration clinique du pancreas et l'injection intraveneuse de secretine purifiee</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18100241" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Studies in pancreatic function; preliminary series of clinical studies with the secretin test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37737818" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6305473" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26211872" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pancreatic exocrine insufficiency in pancreatic cancer: A review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4693931" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/431561" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Non-diabetic retinal abnormalities in chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9149203" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bone mineral density in patients with pancreatic insufficiency and steatorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6922690" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Deficiency of fat-soluble vitamins in treated patients with pancreatic insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8686411" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fat-soluble vitamins in patients with chronic pancreatitis (pancreatic insufficiency).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2784775" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical usefulness of dual-label Schilling test for pancreatic exocrine function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2041378" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Vitamin B12 and folic acid deficiency in chronic pancreatitis: a relevant disorder?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8944569" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8595714" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11444478" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Faecal elastase-1: lyophilization of stool samples prevents false low results in diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7572904" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fecal elastase test: evaluation of a new noninvasive pancreatic function test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9952246" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fecal elastase 1 determination in chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12091856" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : How useful is fecal pancreatic elastase 1 as a marker of exocrine pancreatic disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6602697" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pancreolauryl test. Evaluation of a tubeless pancreatic function test in comparison with other indirect and direct tests for exocrine pancreatic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3888772" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Diagnosis of chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7658271" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Longitudinal evaluation of serum trypsinogen measurement in pancreatic-insufficient and pancreatic-sufficient patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2463138" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Role of serum pancreatic enzyme assays in diagnosis of pancreatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6717495" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Trypsin-like immunoreactivity as a test for pancreatic insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Secretin test diagnoses chronic pancreatitis earlier than ERCP (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14120316" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : RELATIONSHIP BETWEEN MAXIMAL SECRETORY OUTPUT AND WEIGHT OF THE PANCREAS IN THE DOG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6039728" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Secretory response of the human pancreas to continuous intravenous infusion of pancreozymin-cholecystokinin (Cecekin).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/955498" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Use of caerulein with submaximal doses of secretin as a test of pancreatic function in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5437985" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Simultaneous measurements of total pancreatic, biliary, and gastric outputs in man using a perfusion technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7227330" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A comparative evaluation of endoscopic retrograde cholangiopancreatography and the secretin-cholecystokinin test in the diagnosis of chronic pancreatitis: a multicentre study in 124 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Endoscopic retrograde pancreatography and secretin-pancreozymin test in diagnosis of chronic pancreatitis: a comparative evaluation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3877666" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparison of the oral (PABA) pancreatic function test, the secretin-pancreozymin test and endoscopic retrograde pancreatography in chronic alcohol induced pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23711627" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Defining the accuracy of secretin pancreatic function testing in patients with suspected early chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/725516" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The secretin-CCK test and a modified Lundh test. A comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/725498" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A comparative evaluation of endoscopic retrograde pancreatography and secretin-CCK test in the diagnosis of pancreatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3744281" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Exocrine pancreatic function in correlation to ductal and parenchymal morphology in chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7067955" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Relationship between pancreatic exocrine function and ductal morphology in chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3952450" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evaluation of the secretin-cholecystokinin test for chronic pancreatitis by discriminant analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7523260" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of pancreatic morphology and exocrine functional impairment in patients with chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1183860" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pancreatic secretory testing in 1974.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9684658" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prospective evaluation of endoscopic ultrasonography, endoscopic retrograde pancreatography, and secretin test in the diagnosis of chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14707736" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Is a 15-minute collection of duodenal secretions after secretin stimulation sufficient to diagnose chronic pancreatitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18953255" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pancreatic function testing is best determined by the extended endoscopic collection technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17100964" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The efficiency of endoscopic pancreatic function testing is optimized using duodenal aspirates at 30 and 45 minutes after intravenous secretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15332022" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Electrolyte composition of endoscopically collected duodenal drainage fluid after synthetic porcine secretin stimulation in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16454842" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A randomized crossover study of secretin-stimulated endoscopic and dreiling tube pancreatic function test methods in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18294508" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A prospective crossover study comparing secretin-stimulated endoscopic and Dreiling tube pancreatic function testing in patients evaluated for chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20606675" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Endoscopic ultrasound, secretin endoscopic pancreatic function test, and histology: correlation in chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15842594" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The effect of moderate sedation on exocrine pancreas function in normal healthy subjects: a prospective, randomized, cross-over trial using the synthetic porcine secretin stimulated Endoscopic Pancreatic Function Test (ePFT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/428831" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pure pancreatic juice studies in normal subjects and patients with chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9073129" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Intraductal secretin test is as useful as duodenal secretin test in assessing exocrine pancreatic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/707739" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Endoscopic measurement of pancreatic juice secretory flow rates and pancreatic secretory pressures after secretin administration in human controls and in patients with acute relapsing pancreatitis, chronic pancreatitis, and pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16206503" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prospective evaluation of the accuracy of the intraductal secretin stimulation test in the diagnosis of chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18955165" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Evaluation of duct-cell and acinar-cell function and endosonographic abnormalities in patients with suspected chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15017490" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : An endoscopic pancreatic function test with cholecystokinin-octapeptide for the diagnosis of chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22046082" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Update on endoscopic pancreatic function testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14599958" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical application of 13C-Hiolein breath test in assessing pancreatic exocrine insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15012784" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Evaluation of the 13C-triolein breath test for fat malabsorption in adult patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16405545" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Diffusion-weighted MR imaging in the evaluation of pancreatic exocrine function before and after secretin stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20187202" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : MRI and S-MRCP findings in patients with suspected chronic pancreatitis: correlation with endoscopic pancreatic function testing (ePFT).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
